1346441-20-0

Basic information

• Product Name: 1-(3-(1-(4-methoxybenzyl)-7-oxo-1,6,7,8-tetrahydropyrazolo[3,4-b][1,4]diazepin-5-yl)phenyl)-3-(3-morpholino-5-(trifluoromethyl)phenyl)urea
• Synonyms: 1-(3-(1-(4-methoxybenzyl)-7-oxo-1,6,7,8-tetrahydropyrazolo[3,4-b][1,4]diazepin-5-yl)phenyl)-3-(3-morpholino-5-(trifluoromethyl)phenyl)urea
• CAS NO: 1346441-20-0
• Molecular Weight: 633.63
• Mol File: 1346441-20-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1-(3-(1-(4-methoxybenzyl)-7-oxo-1,6,7,8-tetrahydropyrazolo[3,4-b][1,4]diazepin-5-yl)phenyl)-3-(3-morpholino-5-(trifluoromethyl)phenyl)urea(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-(1-(4-methoxybenzyl)-7-oxo-1,6,7,8-tetrahydropyrazolo[3,4-b][1,4]diazepin-5-yl)phenyl)-3-(3-morpholino-5-(trifluoromethyl)phenyl)urea(1346441-20-0)
• EPA Substance Registry System: 1-(3-(1-(4-methoxybenzyl)-7-oxo-1,6,7,8-tetrahydropyrazolo[3,4-b][1,4]diazepin-5-yl)phenyl)-3-(3-morpholino-5-(trifluoromethyl)phenyl)urea(1346441-20-0)

Safety Data

• Hazardous Substances Data: 1346441-20-0(Hazardous Substances Data)

Upstream product

• 121-90-4 m-nitrobenzoic acid chloride 
• 52119-38-7 ethyl 3-oxo-3-(3-nitrophenyl)propanoate 
• 1236202-77-9 1-(4-methoxybenzyl)-4-nitroso-1H-pyrazol-5-amine 
• 1236202-86-0 C₁₂H₁₁F₃N₂O₂ 
• 1346441-44-8 C₂₀H₁₉N₅O₂ 

Relevant articles and documents

Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells

Recently, we have reported the syntheses and antiproliferative activities of N-(5-amino-1-(4-methoxybenzyl)-1H-pyrazol-4-yl amide derivatives on melanoma cells. As a continuous work for antiproliferative agents in melanoma, here we report the synthesis of conformationally rigid analogs, phenyl-6,8- dihydropyrazolo[3,4-b][1,4]diazepin-7(1H)-one derivatives 7a-g, 8a-o and their antiproliferative activities against A375P melanoma cell line and U937 hematopoietic cell line. Most compounds showed competitive antiproliferative activities to sorafenib, the reference standard. Among them, N-(3-(1-benzyl-7-oxo-1,6,7,8-tetrahydropyrazolo[3,4-b][1,4]diazepin-5-yl)phenyl) -4-chloro-3-(trifluoro methyl)benzamide-amino-1-(4-methoxybenzyl)-1H-pyrazol-4- yl)-5-(3-(4-chloro-3-(trifluoromethyl) phenyl) ureido)-2-methylbenzamide (7b) exhibited potent activities (GI50 = 0.43 μM and 0.06 μM) on both cell lines. It has been further confirmed to be a potent and selective Raf kinases inhibitor and also mild inhibitor of PI3Kα.